谱系特异性残留病检测预测停用治疗的慢性髓性白血病患者复发
该前瞻性研究对48例符合停用酪氨酸激酶抑制剂(TKI)标准的慢性髓性白血病患者,在停药时检测5种细胞组分中BCR::ABL1 DNA,发现粒细胞和T细胞中BCR::ABL1 DNA水平在复发患者中更高,并据此在40例首次尝试无治疗缓解(TFR)的患者中划分出3个复发风险不同的组。
要点
- 停药时粒细胞BCR::ABL1 DNA阳性组复发风险为100%,粒细胞阴性/T细胞阳性组为67%,双阴性组为25%。
- 粒细胞和T细胞中BCR::ABL1 DNA水平在复发患者中更高,其他谱系未见此差异。
- 谱系特异性残留病评估有助于筛选高成功期望的TFR尝试者并推迟高复发概率者。
核心结论
- 谱系特异性残留病评估对选择可尝试无治疗缓解(TFR)且成功期望高的患者、同时推迟高复发概率患者具有关键重要性。
研究设计与样本
- 前瞻性研究,对48例符合常规TKI停药标准的慢性髓性白血病患者,在停药时以是/否二分类试验检测5种细胞组分中的BCR::ABL1 DNA。
主要发现
- 复发患者粒细胞和T细胞中BCR::ABL1 DNA中位水平更高,其他谱系未见此差异。
- 40例首次尝试TFR的患者中,粒细胞阳性组复发风险为100%,粒细胞阴性/T细胞阳性组为67%,粒细胞阴性/T细胞阴性组为25%。
关键数值与推荐
- 粒细胞阳性组复发风险100%,粒细胞阴性/T细胞阳性组67%,粒细胞阴性/T细胞阴性组25%(40例首次TFR尝试者)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with chronic myeloid leukemia who are eligible for treatment-free remission (TFR) may still relapse after tyrosine kinase inhibitor (TKI) cessation. There is a need for accurate predictors of outcome to enable patients with a favorable profile to proceed while avoiding futile attempts. Sensitive detection of residual disease in total leukocytes at treatment cessation is associated with relapse but is not highly discriminatory, likely because it is a composite measure of residual leukemia derived from different cell lineages, whereas only some lineages are relevant for relapse. We prospectively measured BCR::ABL1 DNA as a predictive yes/no binary test in 5 cellular fractions from 48 patients meeting conventional criteria for TKI discontinuation. The median BCR::ABL1 DNA level was higher in granulocytes and T cells, but not in other lineages, in patients who relapsed. Among the 40 patients undergoing their first TFR attempt, we defined 3 groups with differing relapse risk: granulocyte-positive group (100%), granulocyte-negative/T-cell-positive group (67%), and granulocyte-negative /T-cell-negative group (25%). These data show the critical importance of lineage-specific assessment of residual disease in the selection of patients who can attempt to achieve TFR with a high expectation of success and, concurrently, defer patients who have a high probability of relapse.
引用
- Pagani IS, Shanmuganathan N, Dang P, et al. Lineage-specific detection of residual disease predicts relapse in patients with chronic myeloid leukemia stopping therapy. Blood. 2023. PMID: 37616555. doi:10.1182/blood.2023021119
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。